42. Prangnell A, Dong H, Daly P, Milloy MJ, Kerr T, Hayashi K. Declining rates of health problems associated
with crack smoking during the expansion of crack pipe distribution in Vancouver, Canada. BMC Public
Health. 2017;17(1):163. doi: 10.1186/s12889-017-4099-9.
43. Scheinmann R, Hagan H, Lelutiu-Weinberger C, et al. Non-injection drug use and Hepatitis C Virus: a
systematic review. Drug Alcohol Depend. 2007;89(1):1-12. doi: 10.1016/j.drugalcdep.2006.11.014.
44. Deiss RG, Rodwell TC, Garfein RS. Tuberculosis and illicit drug use: review and update. Clin Infect Dis.
2009;48(1):72-82. doi: 10.1086/594126.
45. Johnson G, Chamberlain C. (2008) Homelessness and Substance Abuse: Which Comes First?. Australian
Social Work. 2008;61(4):342-356. doi:10.1080/03124070802428191.
46. McKenna SA. "We're Supposed to Be Asleep?" Vigilance, Paranoia, and the Alert Methamphetamine User.
Anthropol Conscious. 2013;24(2):172-190. doi: 10.1111/anoc.12012.
47. Corser J, Palis H, Fleury M., et al. Identifying behaviours for survival and wellness among people who use
methamphetamine with opioids in British Columbia: a qualitative study. Harm Reduct J. 2022;19(46).
https://doi.org/10.1186/s12954-022-00630-8.
48. National Harm Reduction Coalition. Principles of Harm Reduction. Accessed July 30, 2023.
https://harmreduction.org/about-us/principles-of-harm-reduction/.
49. Substance Abuse and Mental Health Services Administration (US); Office of the Surgeon General. Facing
Addiction in America: The Surgeon General's Report on Alcohol, Drugs, and Health [Internet]. US
Department of Health and Human Services. November 2016. PMID: 28252892.
50. Levengood TW, Yoon GH, Davoust MJ, Ogden SN, Marshall BDL, Cahill SR, Bazzi AR. Supervised Injection
Facilities as Harm Reduction: A Systematic Review. Am J Prev Med. 2021;61(5):738-749. doi:
10.1016/j.amepre.2021.04.017.
51. Adeniran E, Quinn M, Wallace R, et al. A scoping review of barriers and facilitators to the integration of
substance use treatment services into US mainstream health care. Drug and Alcohol Dependence Reports.
2023;7(). https://doi.org/10.1016/j.dadr.2023.100152.
52. McGinty EE, Stone EM, Kennedy-Hendricks A, Bachhuber MA, Barry CL. Medication for Opioid Use
Disorder: A National Survey of Primary Care Physicians. Ann Intern Med. 2020;173(2):160-162. doi:
10.7326/M19-3975.
53. Leonieke C. van Boekel, Evelien P.M. Brouwers, Jaap van Weeghel, Henk F.L. Garretsen. Stigma among
health professionals towards patients with substance use disorders and its consequences for healthcare
delivery: Systematic review. Drug and Alcohol Dependence. 2013;131(1–2):23-35.
https://doi.org/10.1016/j.drugalcdep.2013.02.018.
54. Simon R, Snow R, Wakeman S. Understanding why patients with substance use disorders leave the
hospital against medical advice: A qualitative study. Subst Abus. 2020;41(4):519-525. doi:
10.1080/08897077.2019.1671942.
55. Meyerson BE, Bentele KG, Russell DM, et al. Nothing really changed: Arizona patient experience of
methadone and buprenorphine access during COVID. PLoS ONE. 2022;17(10).
https://doi.org/10.1371/journal.pone.0274094.
56. Substance Abuse and Mental Health Services Administration (SAMHSA). Treatment of Stimulant Use
Disorders. National Mental Health and Substance Use Policy Laboratory. June 2020.
https://store.samhsa.gov/sites/default/files/pep20-06-01-001.pdf.
57. The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. J
Addict Med. 2020;14(2S Suppl 1):1-91. doi: 10.1097/ADM.0000000000000633.
58. Hood JE, Banta-Green CJ, Duchin JS, et al. Engaging an Unstably Housed Population with Low-Barrier
Buprenorphine Treatment at a Syringe Services Program: Lessons Learned from Seattle, Washington.
Substance Abuse. 2020;41(3):356-364. doi:10.1080/08897077.2019.1635557.
59. Carter J, Zevin B, Lum PJ. Low barrier buprenorphine treatment for persons experiencing homelessness
and injecting heroin in San Francisco. Addict Sci Clin Pract. 2019;14(20). https://doi.org/10.1186/s13722-
019-0149-1. Accessed August 2, 2023.
60. O'Gurek D, Jatres J, Gibbs J, Latham I, Udegbe B, Reeves K. Expanding buprenorphine treatment to people
experiencing homelessness through a mobile, multidisciplinary program in an urban, underserved setting.
Journal of Substance Abuse Treatment. 2021;127(108342).